Piper Sandler analyst Jason Bednar maintains Masimo (NASDAQ:MASI) with a Neutral and raises the price target from $135 to $150.
Incyte Announces European Commission Approval Of Opzelura Cream For The Treatment Of Non-Segmental Vitiligo With Facial Involvement In Adults And Adolescents
Opzelura® (ruxolitinib) Cream is the first approved treatment in the European Union (EU) to address repigmentation in non-segmental vitiligoPhase 3 data supporting the approval show treatment with Opzelura resulted
